T helper 17 T cells do good for cancer immunotherapy
T helper 17 T cells do good for cancer immunotherapy
复制标题
DOI：
10.2217/imt.09.83
复制
发表时间：
2010-01-01
期刊：
影响因子：
2.8
通讯作者：
Dellabona, Paolo
中科院分区：
文献类型：
--
作者：
Canderan, Glenda;Dellabona, Paolo
评估：Martin-Orozco N，Muranski P，Chung Y等：T辅助17细胞在肿瘤免疫中促进细胞毒性T细胞激活。豁免权31(5)、787-798(2009)。免疫系统在肿瘤控制中起着重要作用。肿瘤抗原特异性的CD4(+)和CD8(+)T细胞正被积极地用于癌症免疫治疗方案，通常获得临床反应。以干扰素-γ的产生为代表的T辅助(Th)1效应细胞因子被认为是控制肿瘤生长的最佳途径。在这项研究中，Martin-Orozco通过证明新定义的Th17效应T细胞比Th1细胞表现出更强的抗肿瘤作用来挑战这一概念。Th17细胞产生强烈的炎性细胞因子IL-17A和IL-17F，到目前为止已经被认为与感染病原体的反应和自身免疫有关。这项研究表明，Th17细胞不仅通过触发强大的非抗原特异性肿瘤内炎症浸润物来预防癌症，而且值得注意的是，还通过提供比Th1细胞更显著的帮助，有效地诱导、扩增、分化和肿瘤归巢肿瘤特异性CD8(+)T细胞。因此，这项研究为Th17细胞的效应功能提供了新的线索，并对将其转化为癌症免疫治疗的临床应用具有重要意义。
Evaluation of: Martin-Orozco N, Muranski P, Chung Y et al.: T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5), 787-798 (2009). The immune system plays an important role in tumor control. Tumor antigen-specific CD4(+) and CD8(+) T cells are being actively exploited in cancer immunotherapy protocols that often attain clinical responses. The T helper (Th)1 effector cytokine profile, epitomized by the production of IFN-gamma, is considered the optimal pathway in controlling tumor growth. In this study, Martin-Orozco challenges this notion by demonstrating that newly defined Th17 effector T cells display a stronger anti-tumor effect vis a vis with Th1 cells. Th17 cells produce the strongly inflammatory cytokines IL-17A and IL-17F, and so far have been implicated in the response to infectious pathogens and in autoimmunity. This study reveals that Th17 cells protect against cancer, not only by triggering a potent nonantigen-specific intratumor inflammatory infiltrate, but also, and remarkably, by providing a more significant help than Th1 cells for the efficient induction, expansion, differentiation and tumor homing of tumor-specific CD8(+) T cells. This study, therefore, sheds new light on the effector functions of Th17 cells and has strong implications for their translation into clinical applications for cancer immunotherapy.